LEO Pharma – a company that focuses on medical dermatology – and ICON have announced a partnership that will enable LEO Pharma to scale clinical trial delivery that is both patient-centric and cost-effective.
The collaboration will also support the company’s wider ambition of building one of the most efficient and effective clinical portfolio in the industry.
In addition, it is hoped that it will improve the lives of dermatology patients with further access to innovative clinical trials and the launch of new medicines. The partnership will operate under the acronym of PACE – reflecting the need to move quickly in order to address modern clinical development challenges.
The name also represents LEO Pharma and ICON’s shared values – Passion, Agility, Communication and Excellence in delivery.
Steve Cutler, CEO at ICON, has high hopes for the partnership: “ICON is delighted to enter this partnership with LEO Pharma that truly takes advantage of our breadth of capability and expertise. We take a flexible and integrated approach when working with our partners, utilising fully outsourced, hybrid and FSP models that complement our partner’s internal capabilities and enable them to achieve their strategic goals.
He added: “It is also motivating for our employees to be working with a partner that shares our values and has a commitment to improving the lives of patients.”
Jörg Möller, Executive Vice President and head of Global R&D at LEO Pharma, explained: “We’ve been exploring several outsourcing models but found a hybrid sourcing model to be the most efficient. Partnering with ICON supports our 2030 strategy as it will help us to bring innovative treatments to patients faster while also supporting a more sustainable business through scalability and flexibility.”
“ICON’s wealth of services and leading position in clinical development will support LEO Pharma’s R&D strategy building on driving innovation through partnerships and support staying competitive,” he concluded.
by John Pinching
Source: pharmatimes.com
CureVac and the University of Texas’s MD Anderson Cancer Center have announced a co-development and licensing agreement to develop novel messenger ribonucleic acid (mRNA)-based cancer vaccines. The strategic collaboration will focus on the development of differentiated cancer vaccine candidates in selected haematological and solid tumour indications with high unmet medical needs.
FUJIFILM Corporation is planning to invest $1.2 billion to expand the planned FUJIFILM Diosynth Biotechnologies manufacturing facility in Holly Springs, North Carolina, US. This news follows the organisation’s announcement of a $2 billion investment in the facility in March 2021. This additional financial boost totals the investment to over $3.2 billion, FUJIFILM confirmed.
Sanofi’s global restructuring and downsizing is now fully underway, with layoffs stretching to the company’s Belgian offices. Belgian newspaper De Tijd reports that 67 employees have been laid off at a site in Ghent and 32 jobs are on the chopping block at Sanofi’s Belgium HQ in Diegem.